Idiopathic pulmonary fibrosis is a rare disease with no known cause that stiffens the lungs tissues in the depths of the lungs. This restricts the organ to work efficiently and provide oxygen to various vital parts of the body. This eventually leads to the disfunctioining of organs like brain and other organs. Idiopathic pulmonary fibrosis affects more 50,000 people every year and 1 out of every 200 adults over the age of 65 in United States itself.
There’s no cure for idiopathic pulmonary fibrosis. The progression of the disease can vary from patient to patient resulting in thickening and scarring of connective tissues in the lungs. Unfortunately, the life expectancy of the diagnosed patient is as short as 5 years. However, there are treatments that lower down the effects of the disease over the patient’s body.
Get Sample Copy of this Report @
Treatment That Can Save Patient’s Life!
In 2011, under a huge PANTHER idiopathic pulmonary trial, evaluation of the various combination of therapies with anti-inflammatory drugs, such as prednisone, azathioprine and acetylcysteine was conducted. However, this research was put to an halt, as a result of high side-effects of heavy inflammation. Couple of months later the research was given the green signal with a substitute drug. The results were astonishing for the members of the trials. They were able to stop the decay of lung’s connective tissue to a remarkable level resulting in increasing the life expectancy of the patient.
Owing to the benefits of the result, a huge door of opportunity was open for the palyers of the global idiopathic pulmonary fibrosis treatment market. They are now able to provide medication to this rare disease making the global idiopathic pulmonary fibrosis treatment market a really lucrative one.
Read Comprehensive Overview of Report @
Truly the new treatment is beneficial for both the patient and the players of global idiopathic pulmonary fibrosis treatment market.